Results 61 to 70 of about 29,030 (239)

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

Frontiers in Immunology, 2021
The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We aimed
J. Riancho, S. Setién, Jose Ramón Sánchez de la Torre, Marta Torres-Barquin, M. Misiego, J. Pérez, T. Castillo-Triviño, Cristina Menéndez-García, M. Delgado-Alvarado   +8 more
semanticscholar   +1 more source

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

AboutOpen
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS).
Roberto Bergamaschi, Marco Capobianco , Roberto Ravasio   +2 more
doaj   +1 more source

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

Frontiers in Immunology, 2023
We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval ...
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado, Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho   +16 more
doaj   +1 more source

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis

Multiple Sclerosis, 2021
Background: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS). Objective: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing ...
Z. V. van Lierop, L. Wieske, Marleen J. A. Koel-Simmelink, M. Chatterjee, I. Dekker, C. Leurs, E. Willemse, B. Moraal, F. Barkhof, F. Eftimov, B. Uitdehaag, J. Killestein, C. Teunissen   +12 more
semanticscholar   +1 more source

Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort

Acta Médica Portuguesa, 2014
Introduction: Natalizumab is licensed as monotherapy for relapsing–remitting multiple sclerosis. Since pivotal studies showing natalizumab efficacy, several subsequent studies confirmed the reduction in annualized relapse rate and the slowing of ...
Ana Teresa Carvalho, Pedro Abreu, Maria José Sá   +2 more
doaj   +1 more source

Patient monitoring during treatment with natalizumab (ORP-24) [PDF]

Neurology Letters, 2023
Natalizumab (Tysabri), a recombinant humanized monoclonal antibody selective for α4- integrin, is indicated for CIS, RRMS, and active SPMS in adults.
Zohreh Abna
doaj  

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis

Diagnostics, 2021
Background: There is a lack of knowledge about the evolution of cerebrospinal fluid (CSF) markers in multiple sclerosis (MS) patients undergoing natalizumab treatment.
Ranjani Ganapathy Subramanian, Dana Horakova, Manuela Vaneckova, Balazs Lorincz, Jan Krasensky, Eva Kubala Havrdova, Tomas Uher   +6 more
doaj   +1 more source

Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis

Neurology
Background and Objectives Patients with pediatric-onset multiple sclerosis (POMS) typically experience higher levels of inflammation with more frequent relapses, and though patients with POMS usually recover from relapses better than adults, patients ...
T. Spelman, Gabrielle Simoneau, Robert Hyde, R. Kuhelj, R. Alroughani, S. Ozakbas, R. Karabudak, B. Yamout, S. Khoury, M. Terzi, C. Boz, D. Horáková, E. Kubala Havrdová, Bianca Weinstock-Guttman, F. Patti, A. Altintas, S. Mrabet, R. Gouider, J. Inshasi, V. Shaygannejad, S. Eichau, W. Ward, H. Butzkueven   +22 more
semanticscholar   +1 more source

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Neurology, 2019
Objective To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID ...
L. Z. Ryerson, J. Foley, I. Chang, I. Kister, G. Cutter, R. Metzger, J. Goldberg, Xiaochun Li, Evan Riddle, K. Smirnakis, R. Kasliwal, Zheng Ren, C. Hotermans, P. Ho, N. Campbell   +14 more
semanticscholar   +1 more source

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo [PDF]

, 2015
Objective: Gut homing of lymphocytes via adhesion molecules has recently emerged as new target for therapy in inflammatory bowel diseases. We aimed to analyze the in vivo homing of effector (Teff) and regulatory (Treg) T cells to the inflamed gut via ...
Agace, Alastair Watson, Anika Fischer, Atreya, Babyatsky, Baumgart, Canavan, Caroline Voskens, Christoph Becker, Clemens Neufert, Danese, Desreumaux, Dustin, Egawa, Fantini, Feagan, Fuss, Gerlach, Gerold Schuler, Ghosh, Haddad, Hamann, Hesterberg, Hoshino, Imke Atreya, Jovani, Kanai, Kempster, Kim, Ley, Li, Macdonald, Markus F Neurath, Matsuzaki, Maul, Neurath, Neurath, Nguyen, Nourshargh, Oki, Papadakis, Picarella, Podolsky, Pryde, Raja Atreya, Rocío López-Posadas, Rott, Rutgeerts, Sandborn, Sandborn, Sebastian Zundler, Shultz, Simon Hirschmann, Strober, Thomas, Tidswell, Timo Rath, Van Assche, Vermeire, Villablanca, Wang, Weninger, Wirtz, Wyant, Wyant   +64 more
core   +1 more source